Renal transplantation is a treatment for end-stage kidney disease, where the kidneys are no longer able to function and transplant into the patient of a donor kidney is required to eliminate patient’ reliance on dialysis. To prevent the risk of rejection of the donor organ lifelong immunosuppression is typically required; the use of such drugs is associated with significant morbidity.
Cymerus™ MSC treatment in a preclinical transplant model demonstrated immunoregulatory effects expected to prevent or reduce organ transplant rejection .
Building on the very encouraging pre-clinical data Cynata is presently developing plans to commence a clinical trial in renal transplant patients, expected to commence in 2021.
 Khan M.A., et al Stem Cell Res Ther. 2019;10(1):290.